Industry Satellite Symposia
The 2024 Multidisciplinary Head and Neck Cancers Symposium Steering Committee has reviewed and approved these symposia as appropriate for presentation as an Industry Satellite Symposia (ISS). The ISS constitutes the content and views of the sponsor and is not part of the official 2024 Multidisciplinary Head and Neck Cancers Symposium program.
Thursday, February 29
Grand Canyon 3
6:00 p.m. - 7:30 p.m.: Dinner and Symposium
Recurrent/Metastatic HNSCC: Harnessing Immunotherapy in Comprehensive Care
Participate in the live session via Zoom.
Register or learn more.
- Distinguish histopathological, molecular and clinical biomarkers that can inform prognosis and management of HNSCC
- Assess emerging efficacy and safety data on novel immune checkpoint inhibitors for recurrent/metastatic HNSCC
- Apply strategies to prevent and mitigate immune-mediated adverse events
- Apply a multidisciplinary team approach to the implementation of surveillance and survivorship care plans for patients with recurrent/metastatic HNSCC
The target audience of this activity includes oncologists, head and neck surgeons, nurse practitioners, physician assistants/associates, oncology nurses and other health care professionals involved in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
- Pre-Activity Assessment
- Recurrent/Metastatic HNSCC: Epidemiology and Clinical Burden
- Diagnosis, Staging and Risk Assessment
- Mechanisms of Immune Escape and Implications for Immunotherapy
- Novel Immune Checkpoint Inhibitors for Recurrent/Metastatic HNSCC: Mechanism of Action, Efficacy and Safety
- Guideline recommendations
- Insights from recent clinical trials: eligibility, end points, study design, dosing/administration, reported efficacy and safety outcomes
- Real-world evidence
- Monitoring and managing immune-related adverse events
- Surveillance and Survivorship Care Essentials
- Case Studies in Interdisciplinary Collaboration: Applying Emerging Evidence in Comprehensive Care Plans for Recurrent/Metastatic HNSCC*
Case studies will be used to foster interactive discussion regarding interdisciplinary strategies to optimize disease control, survival and quality of life in patients with recurrent/metastatic HNSCC. Featured cases will be selected based on their capacity to illustrate diagnostic pathways, the application of novel checkpoint inhibitors, approaches for detecting and managing symptoms and immune-related adverse events, and methods for supporting patients throughout the continuum of care.
- Future Directions in the Management of Recurrent/Metastatic HNSCC
- Review of Key Learning Takeaways and Learner Q&As
- Post-Activity Assessment
- 4-Week Clinical Pearls Learning Retention Email
*Faculty will select the actual patient cases.
Glenn J. Hanna, MD
Director, Center for Cancer Therapeutic Innovation (Early Drug Development Program)
Medical Oncologist, Center for Head and Neck Oncology
Dana-Farber Cancer Institute
Assistant Professor of Medicine, Harvard Medical School
Deborah Wong, MD, PhD
Associate Clinical Professor of Medicine
Division of Hematology-Oncology
UCLA Medical Center
In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
Credit Designation Statement
i3 Health designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
A maximum of 1.5 ANCC contact hours may be earned by learners who successfully complete this nursing continuing professional development activity.
This activity is supported by an independent educational grant from Merck Sharpe & Dohme LLC.
Friday, March 1
Grand Canyon 4-5
6:15 a.m. - 6:45 a.m.: Registration and Breakfast
6:45 a.m. - 7:55 a.m.: Symposium
OncoChallenge in Locally Advanced Head and Neck Cancer: Exploring New Directions
Participate in the live session via Medscape's virtual stream.
Register or learn more.
Join us in Phoenix for a lively quiz show-style symposium on locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). During this interactive activity, experts will review the optimal management of LA SCCHN, from diagnosis and pathophysiology to multidisciplinary management strategies, including promising novel agents. Don’t miss this opportunity to interact with the experts!
Upon completion of this activity, learners will have:
Increased knowledge regarding the:
- Mechanisms of action of treatment approaches used in the treatment of LA SCCHN
- Evolving date evaluating treatment approaches for LA SCCHN
Greater competence related to:
- Developing a patient-centered, multimodal treatment plan to manage LA SCCHN
- Implementing preventive and supportive care strategies to address the toxicities associated with treatment for LA SCCHN
Greater confidence in their ability to incorporate the patient voice in the interdisciplinary care of LA SCCHN.
The target audience for this program is oncologists, radiation oncologists, head and neck surgeons, nurses, pharmacists and other professionals involved in the care of patients with locally advanced squamous cell carcinoma of the head and neck.
Robert Ferris, MD, PhD – Moderator
Director, UPMC Hillman Cancer Center
Hillman Professor of Oncology
UPMC Senior Vice President for Oncology Programs
Associate Vice-Chancellor for Cancer Research
University of Pittsburgh School of Medicine
Nancy Lee, MD, FASTRO – Panelist
Vice Chair, Experimental Therapeutics
Department of Radiation Oncology
Service Chief, Head and Neck Radiation Oncology
Service Chief, Proton Therapy
Memorial Sloan Kettering Cancer Center
Nabil Saba, MD, FACP – Panelist
Professor and Vice Chair, Hematology and Medical Oncology
The Lynne and Howard Halpern Chair in Head and Neck Cancer Research
Director, Head and Neck Oncology
Co-Director Head and Neck CA Multidisciplinary Program
Winship Cancer Institute
In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
Medscape, LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Awarded 1.25 contact hour(s) of nursing continuing professional development for RNs and APNs.
Medscape designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs).
1.25 Interprofessional Continuing Education (IPCE) credit
This activity was planned by and for the health care team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity is supported by an independent educational grant from EMD Serono.